Stimulation of voluntary ethanol intake by cannabinoid receptor agonists in ethanol-preferring sP rats.
BACKGROUND
Recent studies have shown that the cannabinoid CB1 receptor antagonist, SR 141716, is capable of reducing voluntary ethanol intake in rodents, suggesting the involvement of the CB1 receptor in the neural circuitry mediating the positive reinforcing properties of ethanol.


OBJECTIVE
The present study extended to the agonists the investigation on the pharmacological manipulation of ethanol intake by cannabinoid agents.


METHODS
Selectively bred, Sardinian alcohol-preferring (sP) rats were offered ethanol and water under the two-bottle free choice procedure with unlimited access for 24 h/day.


RESULTS
The acute administration of WIN 55,212-2 (0.5-2 mg/kg; IP) and CP 55,940 (3-30 microg/kg; IP) induced a significant, dose-dependent increase in ethanol intake. Conversely, water consumption and intake of regular food and a highly palatable sucrose solution were not affected by treatment with WIN 55,212-2 and CP 55,940. The stimulatory effect of WIN 55,212-2 and CP 55,940 on ethanol intake was completely prevented by administration of SR 141716 (0.3 mg/kg; IP) and the opioid receptor antagonist, naloxone (0.1 mg/kg; IP).


CONCLUSIONS
Administration of WIN 55,212-2 and CP 55,940 promoted voluntary ethanol intake in sP rats. This effect was mediated by stimulation of the cannabinoid CB1 receptor and required the activation of the endogenous opioid system. The results of the present study add further support to the hypothesis that the cannabinoid CB1 receptor is part of the neural substrate regulating ethanol intake. These results are also discussed in terms of WIN 55,212-2 and CP 55,940 administration possibly fixing to a higher level the hedonic set-point mechanism regulating ethanol drinking behavior in sP rats.
Colombo
Giancarlo
G
CNR Institute of Neurogenetics and Neuropharmacology, c/o Department of Neuroscience, University of Cagliari, S.S. 554, Km 4.5, I-09042, Monserrato (CA), Italy. colomb@unica.it
Serra
Salvatore
S
Brunetti
Giuliana
G
Gomez
Raquel
R
Melis
Samuele
S
Vacca
Giovanni
G
Carai
Mauro M
MM
Gessa
Luigi
L
D000284:Administration, Oral; D000428:Alcohol Drinking / Q000235:genetics; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D048588:Benzoxazines; D003511:Cyclohexanols / Q000494:pharmacology; D008297:Male; D009025:Morpholines / Q000494:pharmacology; D009281:Naphthalenes / Q000494:pharmacology; D051381:Rats; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists* / Q000037:antagonists & inhibitors / Q000502:physiology; D013395:Sucrose / Q000008:administration & dosage
D000700:Analgesics; D048588:Benzoxazines; D003511:Cyclohexanols; D009025:Morpholines; D009281:Naphthalenes; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; D013395:Sucrose; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol